Glycorex Transplantation AB (publ): Interim Report January - June 2023
April - June 2023 · Net sales: SEK 9.1 million (11.2) · Operating income: SEK -3.9 million (-1.7) · Net income for the period: SEK -3.9 million (-1.7) · Earnings per share: SEK -0.05 (-0.02) Summary of the quarter · Decreased sales by 19% despite the second best second quarter in ten years. · The first blood group incompatible kidney transplants with Glycosorb® ABO are performed in Hong Kong and Belgium. · Training and start-up of our technology in six new transplant centers. · Glycorex participates in three international transplantation congresses. ·